In patients with type 2 diabetes, studies reported a relative increase in NAION risk with GLP-1 receptor agonists, mainly semaglutide, from nonsignificant to fourfold; the absolute number affected stayed low and no causal link was shown.
In plain wordsIn type 2 diabetes, studies of GLP-1 drugs, mainly semaglutide, found optic nerve vision loss risk from no clear rise to fourfold. No cause shown.
- Peptide
- Semaglutide
- Outcome
- IncreaseNAION risk with GLP-1 receptor agonist use in type 2 diabetes
- Study
n: not reported in source
- Outcome group
- Adverse events · Eye
Source sentences
Across studies including patients with T2D, the relative increase in NAION risk associated with the use of a GLP-1 RA, mainly semaglutide, ranged from nonsignificant to fourfold, while the absolute number of affected patients remained low.
2 context sentences(design, population, supporting numbers)
Given the retrospective design of the main studies, no causal link could be established between the use of GLP-1RAs and NAION.
A literature search strategy was conducted for all English-language literature with a systematic review of key references up to April 2025.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.